Forthcoming practical framework for ethics committees and researchers on post-trial access to the trial intervention and healthcare

When research concludes, post-trial access (PTA) to the trial intervention or standard healthcare can be crucial for participants who are ill such as those in resource-poor countries with inadequate healthcare, British participants testing ‘last-chance drugs’ unavailable on the National Health Servi...

Full description

Saved in:  
Bibliographic Details
Authors: Sofaer, Neema (Author) ; Lewis, Penney (Author) ; Davies, Hugh (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2014
In: Journal of medical ethics
Year: 2014, Volume: 40, Issue: 4, Pages: 217-218
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816147818
003 DE-627
005 20230426115753.0
007 cr uuu---uuuuu
008 220908s2014 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2013-101398  |2 doi 
035 |a (DE-627)1816147818 
035 |a (DE-599)KXP1816147818 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Sofaer, Neema  |e VerfasserIn  |4 aut 
245 1 0 |a Forthcoming practical framework for ethics committees and researchers on post-trial access to the trial intervention and healthcare 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a When research concludes, post-trial access (PTA) to the trial intervention or standard healthcare can be crucial for participants who are ill such as those in resource-poor countries with inadequate healthcare, British participants testing ‘last-chance drugs’ unavailable on the National Health Service (NHS) and underinsured US participants. Yet, many researchers are unclear about their obligations regarding the post-trial period, and many research ethics committees (RECs) do not know what to require of researchers. Consequences include participants who reasonably expect but lack PTA to the trial intervention, unplanned financial liabilities for NHS Trusts forced to fund this, negative press and potential to undermine public trust.1-3,iOne reason for the lack of clarity is controversy over whether and when participants should have access, after the study, to the study intervention. At one extreme is the view that continued access should be ensured when the intervention has benefited the participant or when it has proven safe and effective for the participant population, irrespective of the cost and burden of ensuring continued access. At the other extreme is the view that continued access need never be provided so long as non-availability of the study intervention post-trial was adequately disclosed when participants were invited to participate.6 There is also disagreement about when poststudy access to the study intervention should be considered beneficial for participants. The spectrum ranges from the view that the intervention should be regarded as beneficial for a proposed use only after the … 
601 |a Intervention 
700 1 |a Lewis, Penney  |e VerfasserIn  |4 aut 
700 1 |a Davies, Hugh  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 40(2014), 4, Seite 217-218  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:40  |g year:2014  |g number:4  |g pages:217-218 
856 |3 Volltext  |u http://www.jstor.org/stable/43282965  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/medethics-2013-101398  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/40/4/217.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185601719 
LOK |0 003 DE-627 
LOK |0 004 1816147818 
LOK |0 005 20220908053620 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#9C71F1E143955EBD98C413E5F993AF0776CEE3B8 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/43282965 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw